Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and general safety statements are supported by the provided label excerpts, but multiple claims extend beyond what is supported in the supplied labeling text (e.g., obesity indication, specific study quantitative effects on sugar intake, and detailed effects framed as reducing glucose absorbed/sugar intake).
Category Scores
Accurate Statements
Ozempic belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists.
11 DESCRIPTION; 12.1 Mechanism of Action (semaglutide is a GLP-1 receptor agonist)
Ozempic works by mimicking the action of the natural hormone GLP-1.
11 DESCRIPTION (GLP-1 receptor agonist/analog); 12.1 Mechanism of Action (native GLP-1 target via GLP-1 receptor activation)
Ozempic stimulates the release of insulin.
12.1 Mechanism of Action (stimulates insulin secretion in a glucose-dependent manner)
Ozempic slows down the movement of food from the stomach to the small intestine.
12.1 Mechanism of Action (minor delay in gastric emptying in early postprandial phase)
In rare cases, Ozempic can cause pancreatitis.
5.2 Acute Pancreatitis (acute pancreatitis observed in patients treated with GLP-1 receptor agonists, including OZEMPIC)
In rare cases, Ozempic can cause thyroid cancer.
WARNING: RISK OF THYROID C-CELL TUMORS (rodents develop thyroid C-cell tumors; human relevance not determined) and boxed warning counseling language for thyroid tumors
Common side effects of Ozempic include nausea, vomiting, and diarrhea.
5 WARNINGS AND PRECAUTIONS (5.7 references gastrointestinal adverse reactions; 17 PATIENT COUNSELING includes persistent nausea/vomiting/diarrhea in acute kidney injury due to volume depletion context)
GLP-1 is released in response to food intake.
Not supported in the provided excerpts (no statement found in supplied label text)
Unsupported Statements
Ozempic (semaglutide) is an injectable medication used to treat type 2 diabetes and obesity.
The provided label excerpts list indications for type 2 diabetes and cardiovascular/kidney risk reduction, but do not provide an indication for obesity.
Ozempic can significantly reduce sugar intake in individuals with type 2 diabetes.
No provided label excerpt states that OZEMPIC reduces sugar intake in individuals, nor provides evidence for 'significantly reduce sugar intake.'
In a cited study, patients taking Ozempic had a 25% reduction in sugar intake compared to those taking placebo.
No quantitative study results (25% reduction in sugar intake vs placebo) appear in the supplied label excerpts.
In a cited study, Ozempic treatment led to an average of 30 grams less sugar per day compared with patients in that study.
No quantitative study results (30 grams less sugar per day) appear in the supplied label excerpts.
Ozempic reduces sugar intake by slowing down gastric emptying.
The label excerpt supports delayed gastric emptying, but does not support a direct causal claim that this results in reduced sugar intake.
Slowing gastric emptying allows for more gradual release of glucose into the bloodstream.
The provided label excerpt mentions a minor delay in gastric emptying, but does not state 'more gradual release of glucose into the bloodstream.'
Ozempic reduces the amount of glucose absorbed by the body, leading to decreased sugar intake.
The provided label excerpt describes glucose lowering via stimulating insulin secretion and lowering glucagon (glucose-dependent) and a minor delay in gastric emptying; it does not state reduced glucose absorption or decreased sugar intake.
GLP-1 helps to slow down gastric emptying.
The provided label excerpt supports GLP-1 receptor actions generally, but does not specifically state that GLP-1 slows gastric emptying.
GLP-1 reduces the amount of glucose absorbed by the body.
Not supported in the provided excerpts; no statement about reducing glucose absorption.
Ozempic stimulates the release of GLP-1.
The label excerpt describes semaglutide as a GLP-1 receptor agonist; it does not state that semaglutide stimulates endogenous GLP-1 release.
Ozempic affects food choices by reducing cravings for sweet and high-calorie foods.
Not supported in the provided label excerpts.
Patients taking Ozempic should monitor sugar intake closely with their healthcare provider and adjust the treatment plan as needed.
The provided label excerpts include various patient counseling items and monitoring for pancreatitis/thryoid symptoms and other warnings, but do not instruct patients to monitor 'sugar intake closely' or adjust treatment plan based on sugar intake.
Contradictions
Low
AI Statement
Ozempic (semaglutide) is an injectable medication used to treat type 2 diabetes and obesity.
Label Reference
Section 1 INDICATIONS AND USAGE (provided excerpt does not list obesity as an indication)
Important Omissions
FDA-label indications beyond glycemic control in adults with type 2 diabetes (reductions in risk of major adverse cardiovascular events; reductions in risk of sustained eGFR decline/end-stage kidney disease/cardiovascular death in adults with type 2 diabetes and chronic kidney disease).
Importance:
Moderate
Boxed warning contraindication details (e.g., contraindicated in patients with personal/family history of MTC or MEN 2) were not included in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While pancreatitis and thyroid C-cell tumor risk messaging aligns directionally with the label excerpts, several claims introduce unsupported causal or quantitative statements about sugar intake and cravings, and the 'monitor sugar intake closely' instruction is not supported by the provided labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the supplied label excerpts (especially obesity indication and quantitative/causal statements about sugar intake, absorption, glucose release, cravings).
Suggested Improvement
Restrict statements to label-supported indications (type 2 diabetes glycemic control plus CV/kidney risk reductions) and mechanism details stated in the provided excerpts (GLP-1 receptor agonism; glucose-dependent insulin secretion; delayed gastric emptying). Remove unsupported quantitative study claims and any specific instructions not present in the provided labeling.